Home › Funds › Crestline Management, L.P. › DNLI
Crestline Management, L.P. position in DNLI
DENALI THERAPEUTICS INC · Health Care
Crestline Management, L.P. reported holding 1,910,732 shares of DNLI (DENALI THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$49.1M, representing 91.90% of its reported portfolio and ranking #1 among its reported holdings. Crestline Management, L.P. has disclosed DNLI holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Crestline Management, L.P.'s DNLI position evolved
Crestline Management, L.P. first disclosed a stake in DNLI in Q3 2023 at 5,960,732 shares (US$123.0M). The position peaked in Q3 2024 at 4,460,732 shares, worth US$129.9M. Across 12 filings, Crestline Management, L.P. increased the stake 0 time(s), trimmed it 11 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,910,732 shares valued at US$49.1M — a reduction of -300,000 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 5.96M | $122.97M | New |
| Q4 2023 | 5.66M | $121.48M | Reduce |
| Q1 2024 | 5.21M | $106.92M | Reduce |
| Q2 2024 | 4.76M | $110.54M | Reduce |
| Q3 2024 | 4.46M | $129.94M | Reduce |
| Q4 2024 | 4.31M | $87.85M | Reduce |
| Q1 2025 | 4.16M | $56.57M | Reduce |
| Q2 2025 | 3.86M | $54.01M | Reduce |
| Q3 2025 | 3.41M | $49.52M | Reduce |
| Q4 2025 | 2.81M | $46.41M | Reduce |
| Q1 2026 | 2.21M | $42.45M | Reduce |
| Q2 2026 | 1.91M | $49.14M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DNLI and 13F data
DNLI (DENALI THERAPEUTICS INC) is a Health Care company. 44 other funds we track also report a position in DNLI — the largest reported positions include Temasek Holdings (US$180.4M), Temasek Holdings (Private) Ltd (US$180.4M), BAKER BROS. ADVISORS LP (US$96.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DNLI
- Temasek Holdings 7.01M sh · $180.37M · Q2 2026
- Temasek Holdings (Private) Ltd 7.01M sh · $180.37M · Q2 2026
- BAKER BROS. ADVISORS LP 3.73M sh · $96.05M · Q2 2026
- Casdin Capital 2.04M sh · $52.60M · Q2 2026
- Foresite Capital Management VI LLC 1.40M sh · $35.92M · Q2 2026
- Siren, L.L.C. 1.40M sh · $35.92M · Q2 2026
- ADAR1 Capital Management, LLC 1.03M sh · $26.47M · Q2 2026
More on Crestline Management, L.P.
FAQ
How long has Crestline Management, L.P. held DNLI?
Crestline Management, L.P. has disclosed DNLI holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Crestline Management, L.P.'s current position in DNLI?
As of Q2 2026, Crestline Management, L.P. holds 1.91M shares of DNLI (DENALI THERAPEUTICS INC), valued at $49.14M, representing 91.90% of its reported portfolio and ranking #1.
Has Crestline Management, L.P. been buying or selling DNLI?
In the latest 13F filing (Q2 2026), Crestline Management, L.P. reduced its position in DNLI. The position peaked in Q3 2024 at 4.46M shares.
Which other funds hold DNLI?
Other major institutional holders of DNLI include Temasek Holdings, Temasek Holdings (Private) Ltd, BAKER BROS. ADVISORS LP, among 44 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.